Media Room

Here you can find news, a variety of media and other useful information on us

Featured articles

EP0031 poster presented at ASCO 2024

Phase 1 study data for EP0031/A400, presented at ASCO 2024 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1717506230986%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2024%252F05%252FASCO_2024_Poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted [...]

Read more

Ellipses’ EP0031/A400 cleared to start Phase 2

Ellipses’ next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2 clinical development Drug has successfully completed US Food and Drug Administration’s End of Phase 1 data review. Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the [...]

Read more

Streamlining drug development processes

Ellipses Pharma features in the Guardian Innovations In Oncology and Imaging Series As part of The Guardian's Innovations in Oncology and Imaging series, our CEO Rajan Jethwa, CMO Professor Tobi Arkenau and Head of CMC Graeme Horne explain how our streamlined approach to drug development is meeting patients' needs quicker. To read the full article [...]

Read more

Accelerating development of critical cancer drugs

Ellipses Pharma features in the Guardian Innovations In Oncology and Imaging Series As part of The Guardian's Innovations in Oncology and Imaging series, our Chairman and Co-Founder Professor Sir Chris Evans OBE, and our CMO Professor Tobi Arkenau explain how our unique and disruptive drug development model is accelerating the development of potential new cancer [...]

Read more

Want to learn more?